- Current report filing (8-K)
November 13 2008 - 3:17PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
November
7, 2008
Date
of Report
(Date
of earliest event reported)
PRO-PHARMACEUTICALS,
INC.
(Exact
name of Registrant as specified in its charter)
Nevada
|
000-32877
|
04-3562325
|
(State
or other jurisdiction of
incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
7 Wells Avenue
Newton, Massachusetts 02459
|
|
(Address
of principal executive offices)
(Zip
code)
|
(617) 559-0033
(Registrant’s telephone number, including
area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing
Rule or Standard; Transfer of Listing.
The Company received a letter dated November 7, 2008 from the NYSE
Alternext US (the "Exchange"), formerly known as the American Stock
Exchange, stating that the Exchange intends to begin delisting
proceedings of the Company’s common stock because the Company was not
able to regain compliance with Section 1003(a)(i) of the Company Guide
with stockholders’ equity of less than $2,000,000 and losses from
continuing operations and net losses in two out of its three most recent
fiscal years, and Section 1003(a)(ii) of the Company Guide with
stockholders’ equity of less than $4,000,000 and losses from continuing
operations and net losses in three of its four most recent fiscal
years. The Company has appealed the Exchange’s decision and requested a
hearing before the Exchange’s Corporate Compliance Panel, but cannot
assure that the Exchange’s decision will be reversed. If the
Company’s common stock is delisted, the shares may trade on another
market, including the Over-the-Counter Bulletin Board.
Item
9.01 Financial Statements and Exhibits.
|
(a)
|
Financial Statements of Businesses Acquired.
|
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
|
(b)
|
Pro Forma Financial Information.
|
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
|
(c)
|
Shell Company Transactions
|
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
|
(d)
|
Exhibits.
|
|
|
|
|
|
|
|
|
|
Exhibit Number
|
|
|
|
|
|
|
|
|
99.1
|
News release of Pro-Pharmaceuticals, Inc., dated November 13, 2008,
entitled “Pro-Pharmaceuticals Receives Delisting Notice From NYSE
Alternext US”.
|
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
PRO-PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Anthony D. Squeglia
|
|
|
|
Anthony D. Squeglia
|
|
|
|
Chief Financial Officer
|
|
|
|
|
Date:
|
November 13, 2008
|
|
|
EXHIBIT
INDEX
Exhibit
Number
|
Description
|
|
|
99.1
|
News release from Pro-Pharmaceuticals, Inc., dated November 13,
2008, entitled “Pro-Pharmaceuticals Receives Delisting Notice From
NYSE Alternext US”.
|
Pro (AMEX:PRW)
Historical Stock Chart
From May 2024 to Jun 2024
Pro (AMEX:PRW)
Historical Stock Chart
From Jun 2023 to Jun 2024